NCT06838611 ChAracterization of Patients and Treatment OUtcomes in Severe Tricuspid Regurgitation
| NCT ID | NCT06838611 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Warsaw |
| Condition | Tricuspid Regurgitation |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2023-11-14 |
| Primary Completion | 2027-11-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2023-11-14 with a primary completion date of 2027-11-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to characterize the population of patients qualified for transcatheter tricuspid valve interventions (TTVI). It is expected to: * Describe the profile of patients qualified for TTVI * Establish the most common causes for disqualification from TTVI * Evaluate the immediate and long-term efficacy of TTVI * Evaluate TTVI safety Participants will undergo a standard qualification procedure for TTVI and then will be subject to a follow-up consisting of clinical examination, echocardiography and laboratory testing.
Eligibility Criteria
Inclusion Criteria: * tricuspid regurgitation * qualification for transcatheter tricuspid valve intervention Exclusion Criteria: * tricuspid regurgitation qualified for surgical treatment * concomitant left heart valve disease qualified for surgical treatment * multivessel coronary artery disease qualified for coronary artery bypass grafting * lack of patient's consent to enter the registry
Contact & Investigator
Adam Rdzanek, MD PhD
PRINCIPAL INVESTIGATOR
First Department of Cardiology, Medical University of Warsaw
Frequently Asked Questions
Who can join the NCT06838611 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Tricuspid Regurgitation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06838611 currently recruiting?
Yes, NCT06838611 is actively recruiting participants. Contact the research team at adam.rdzanek@wum.edu.pl for enrollment information.
Where is the NCT06838611 trial being conducted?
This trial is being conducted at Warsaw, Poland.
Who is sponsoring the NCT06838611 clinical trial?
NCT06838611 is sponsored by Medical University of Warsaw. The principal investigator is Adam Rdzanek, MD PhD at First Department of Cardiology, Medical University of Warsaw. The trial plans to enroll 300 participants.